Analysis of the influence of dabigatran on coagulation factors and inhibitors

International Journal of Laboratory Hematology

Volumn 37, Issue 2, 2015, Pages 225-230

  Tsutsumi, Y ^a   Shimono, J ^a   Ohhigashi, H ^a   Ito, S ^a   Shiratori, S ^a   Teshima, T ^b  

^a Hakodate Municipal Hospital   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Antifactor VIII inhibitor; Coagulation factors; Dabigatran

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8 INHIBITOR; DABIGATRAN; PROTEIN C; PROTEIN S; PROTHROMBIN; THROMBOPLASTIN; BLOOD CLOTTING INHIBITOR;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; FEMALE; FISHER EXACT TEST; HEART ATRIUM FIBRILLATION; HISTORY; HUMAN; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; THROMBOELASTOGRAPH; BLOOD; BLOOD CLOTTING TEST; MIDDLE AGED; REPRODUCIBILITY; STANDARDS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION FACTORS; BLOOD COAGULATION TESTS; DABIGATRAN; FEMALE; HUMANS; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; YOUNG ADULT;

EID: 84924763769     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/ijlh.12270     Document Type: Article

References (23)

1. Baetz BE, Spinler SA. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy 2001;28:1354-73.
2. Stangier J, Rathgen K, Stahle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010;49:259-68.
3. Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med 2012;366:864-6.
4. Legrand M, Mateo J, Aribaud A, Ginisty S, Eftekhari P, Huy PT, Drouet L, Payen D. The use of dabigatran in elderly patients. Arch Intern Med 2011;171:1285-6.
5. Radecki RP. Dabigatran: uncharted waters and potential harms. Ann Intern Med 2012;157:66-8.
6. Huisman MV, Lip GY, Diener HC, Brueckmann M, van Ryn J, Clemens A. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 2012;107:838-47.
7. eMC. Summary of Product Characteristics: Prada. 2012 (Last update on eMC:30/04/2012); http://www.medicines.org.uk/emc/medicine/24839/SPC.
8. Giles AR, Verbruggen B, Rivard GE, Teitel J, Walker I. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII: C inhibitors in the haemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis. Thromb Haemost 1992;79:872-5.
9. Product information. Pradaxa (Dabigatran Etexilate Mesylate). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2012.
10. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008;47:285-95.
11. Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 2009;15:9S-16S.
12. Stangier J, Eriksson BI, Dahl OE, Ahnfelt L, Nehmiz G, Stahle H, Rathgen K, Svard R. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005;45:555-63.
13. Stangier J, Rathgen K, Stahle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007;64:292-303.
14. Connolly S, Ezekowitz M, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
15. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ, RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-52.
16. Adcock DM, Gosselin R, Kitchen S, Dwyre DM. The effect of dabigatran on select specialty coagulation assays. Am J Clin Pathol 2013;139:102-9.
17. Eby C. Novel anticoagulants and laboratory testing. Int J Lab Hematol 2013;35:262-8.
18. Baglin T. Clinical use of new oral anticoagulant drugs: dabigatran and rivaroxaban. Br J Haematol 2013;163:160-7.
19. Franchini M, Capra F, Nicolini N, Veneri D, Manzato F, Baudo F, Lippi G. Drug-induced anti-factor VIII antibodies: a systemic review. Med Sci Monit 2007;13:RA55-61.
20. Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012;23:138-43.
21. Alikhan R, Rayment R, Keeling D, et al. The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran. Emerg Med J 2014;2:163-8.
22. Dager WE, Gosselin RC, Roberts AJ. Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity. Crit Care Med 2013;41:e42-6.
23. Siegel DM, Gracia DA, Crowther MA. How I treat target-specific oral anticoagulant-associated bleeding. Blood 2014;123:1152-8.